DXB
Dimerix Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 53.33%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
20
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.
📈 Performance
Price History
+4391.37%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.39
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in DXB
20
📊 Total Capital Earnings
$32K
🔃 Average investment frequency
48 weeks
💵 Average investment amount
$1,241
⏰ Last time a customer invested in DXB
7 days
DXB investor breakdown
💵 Income of investors
More than 200k
150k - 200k
9%
100k - 150k
32%
50k - 100k
32%
Less than 50k
23%
👶 Age of investors
18 - 25
15%
26 - 34
35%
35 - 90
50%
🙋 Legal gender of investors
Female
35%
Male
65%
Pearlers who invest in DXB also invest in...
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.71%
📊 Share price
$66.50 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.85%
📊 Share price
$100.90 AUD
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA
🧱 MATERIALS
💸 FINANCIALS
DXBN
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing new therapies in areas with unmet medical needs for global markets. The company is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. The company has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
18.86%
📊 Share price
$57.74 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
🙌 Performance (5Yr p.a)
48.36%
📊 Share price
$0.19 AUD
📈 HIGH PRICE GROWTH
🧬 BIOTECHNOLOGY
Want more shares? Try these...
Dexus Convenience Retail REIT engages in owning and management of portfolio of properties. The company is headquartered in Sydney, New South Wales and currently employs 0 full-time employees. The company went IPO on 2017-07-27. The Fund's portfolio is valued at approximately $781 million, is predominantly located on Australia's eastern seaboard and leased to Australian and international convenience retail tenants. The portfolio has a long weighted average lease expiry and contracted annual rent increases, providing a high level of income security. The Fund has a conservative approach to capital management with a target gearing range of 25-40%. The Fund consists of three registered managed investment schemes domiciled in Australia: Convenience Retail REIT No. 1, Convenience Retail REIT No. 2 and Convenience Retail REIT No. 3. The Fund's manager is Convenience Retail Management Pty Ltd.
🙌 Performance (5Yr p.a)
-2.62%
📊 Share price
$2.99 AUD
💰 HIGH DIVIDEND
🏠 REAL ESTATE
Develop Global Ltd. engages in the exploration and production of mine base and precious metal resources. The firm is also involved in operations of its underground mining services division Develop Mining Services Its segments include mining services and mining and exploration. The Company’s projects include Sulphur Springs Project, Whim Creek Joint Venture, Woodlawn Project, Pioneer Dome, and Kangan Gold Project. The Sulphur Springs project is located 144 kilometers (km) to the southeast of Port Hedland and includes the Sulphur Springs and Kangaroo Caves deposits together with tenements along the 27 km Panorama Trend that contains six advanced targets that have returned intersections of commercial grade copper and zinc. The Whim Creek Joint Venture Project is located 115 km to the southwest of Port Hedland. The Woodlawn Project is a zinc-copper-lead-gold-silver project located in the Lachlan Fold belt in New South Wales, 250 km south-west of Sydney and 40 km south of Goulburn.
🙌 Performance (5Yr p.a)
302.62%
📊 Share price
$2.46 AUD
⛏️ MINING
